Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BMY stock price vs ILMN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ILMN's multiple
Needs ILMN P/E.
Implied fair value · at BMY's multiple
Needs BMY P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
13 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BRISTOL-MYERS SQUIBB COMPANY · implied price per share
Bear
$50.67
Base
$61.69
Bull
$77.14
Illumina, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
BMY vs PFE
Merck & Co., Inc.
BMY vs MRK
AbbVie Inc.
BMY vs ABBV
Eli Lilly and Company
BMY vs LLY
Amgen Inc.
BMY vs AMGN
Gilead Sciences, Inc.
BMY vs GILD
THERMO FISHER SCIENTIFIC INC.
BMY vs TMO
AGILENT TECHNOLOGIES, INC.
BMY vs A
DANAHER CORP /DE/
BMY vs DHR
BIO-RAD LABORATORIES, INC.
BMY vs BIO
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
BMY vs PACB
Natera, Inc.
BMY vs NTRA
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BMY can sustain its current profitability and manage leverage without material deterioration, then BMY looks attractive relative to ILMN because it trades at a steep discount on earnings, sales, and enterprise-value multiples while sitting inside its DCF range.
BMY appears materially cheaper than ILMN across P/E, P/S, EV/EBITDA, and EV/Revenue, while the model implies a much higher value than the current price. The valuation gap is supported by BMY's lower multiples despite comparable revenue growth and broad profitability.
Supporting Metrics
